Thorough assessment of the effectiveness of belimumab in a large Spanish multicenter cohort of systemic lupus erythematosus patients

  • Published on 03/29/2024
  •  Reading time: 4 min.

Irene Altabás-González, 1, José María Pego-Reigosa, 1, Coral Mouriño, 2, Norman Jiménez, 2, Andrea Hernández-Martín, 3, Ivette Casafont-Solé, 4, Judit Font Urguelles, 4, José Andrés Román-Ivorra, 5, Marta de la Rubia Navarro, 6, María Galindo-Izquierdo, 7, Tarek Carlos Salman-Monte, 8, Javier Narváez, 9, Paola Vidal-Montal, 10, María Jesús García-Villanueva, 11, Sandra Garrote-Corral, 10, María Ángeles Blázquez-Cañamero, 12, Carlos Marras, 13, María Piqueras-García, 13, Julia Martínez-Barrio, 14, Marina Sánchez-Lucas, 15, Josefina Cortés-Hernández, 16, Eleonora Penzo, 16, Jaime Calvo, 17, Juan Ramón de Dios, 17, Belén Álvarez Rodríguez, 17, Margarida Vasques-Rocha, 17, Eva Tomero, 18, Raúl Menor-Almagro, 19, Myriam Gandía, 19, José A Gómez-Puerta, 20, Beatriz Frade-Sosa, 20, Consuelo Ramos-Giráldez, 21, Carmen Trapero-Pérez, 21, Elvira Diez, 22, Clara Moriano, 22, Alejandro Muñoz-Jiménez, 23, Iñigo Rúa-Figueroa 3

1 Department of Rheumatology, Complexo Hospitalario Universitario de Vigo, Galicia Sur Health Research Institute, Rheumatology and Inmuno-Mediated Diseases Reasearch Group (IRIDIS), Vigo, Spain
2 Deparment of Rheumatology, Galicia Sur Health Research Institute, Rheumatology and Inmuno-Mediated Diseases Reasearch Group (IRIDIS), Vigo, Spain
3 Department of Rheumatology, Hospital Universitario Doctor Negrín, Las Palmas de Gran Canaria, Spain
4 Department of Rheumatology, Germans Trias i Pujol University Hospital, LCMN, Germans Trias i Pujol Research Institute (IGTP), Barcelona, Spain
5 Department of Rheumatology, Hospital Universitari i Politècnic La Fe. Facultad de Medicina y Ciencias de la Salud. Universidad Católica de Valencia, Valencia, Spain
6 Department of Rheumatology, Hospital Universitari i Politècnic La Fe, Valencia, Spain
7 Department of Rheumatology, University Hospital “12 de Octubre”, Madrid, Spain
8 Department of Rheumatology, Hospital del Mar/Parc de Salut Mar-IMIM, Barcelona, Spain
9 Deparment of Rheumatology, Hospital Universitario de Bellvitge-Instituto de Investigación Biomédica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Barcelona, España
10 Department of Rheumatology, Hospital Universitario de Bellvitge, Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain
11 Deparment of Rheumatology, Hospital Universitario Ramon y Cajal, Madrid, Spain
12 Deparment of Rheumatology, Severo Ochoa Hospital, Madrid, Spain
13 Department of Rheumatology, Hospital Universitario Virgen de Arrixaca, Murcia, Spain
14 Deparment of Rheumatology, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Biomédica, Universidad Complutense de Madrid, Hospital Gregorio, Madrid, Spain
15 Deparment of Rheumatology, Hospital General Universitario Gregorio Marañón, Madrid, Spain
16 Department of Rheumatology, Vall d'Hebron Research Institute, Barcelona, Spain
17 Department of Rheumatology, Hospital Universitario de Araba, Vitoria, Spain
18 Department of Rheumatology, Hospital Universitario de la Princesa, Madrid, Spain
19 Deparment of Rheumatology, Hospital Universitario de Jerez, Cádiz, Spain
20 Department of Rheumatology, Hospital Clinic and IDIBAPS, Barcelona, Spain
21 Department of Rheumatology, Hospital Universitario Virgen de Valme, Sevilla, Spain
22 Deparment of Rheumatology, Complejo Asistencial Universitario de León, León, Spain
23 Department of Rheumatology, Hospital Universitario Virgen del Rocío, Seville, Spain

Corresponding author: Íñigo Jesús Rúa-Figueroa Fernández de Larrinoa, Rheumatology Department, Hospital Universitario de Gran Canaria Dr Negrín, Las Palmas de Gran Canaria, C. Pl. Barranco de la Ballena, s/n, 35010 Las Palmas de Gran Canaria, Las Palmas, iruafer@gobiernodecanarias.org Phone: 34 + 928450604

Abstract

Objectives To provide an overview on the current use of belimumab (BLM) in SLE patients in clinical practice and to examine its efficacy in terms of standardized outcomes, drug survival, as well as patient and safety profiles.
Methods A longitudinal retrospective multicentre cohort including SLE patients treated with BLM at 18 Spanish centers. Data was collected upon initiation of BLM, at 6 and 12 months after initiation, and at the last recorded...

ContentGeneMD

To continue reading this article in Full-Text...

* Access is totally free, without commitment or condition. Service exclusively reserved for healthcare professionals.

Peer-Reviewed Journals A-Z

Search | Advanced search

Get the latest news in Rheumatology

Receive our newsletter to stay up to date with the latest news in Rheumatology